Biocon Limited has informed the Exchange regarding a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach".
Biocon Limited Press Release Sep 21 2026
Filed with NSE · · 3 pages · English
Release
Earlier from Biocon
- Biocon Limited Press Release Sep 08 2026
- Biocon Announces Supplemental U.S. FDA Approval For Prefilled Autoinjector For YESINTEK
- Biocon Launches Aflibercept Biosimilar In The United States
- Biocon Limited Press Release Aug 05 2026
- Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg
Later from Biocon
- Biocon's Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach
- Biocon Limited has informed the Exchange regarding a press release dated October 29, 2026, titled "Biocon Named Among Science Magazine s Best Employers in Global Biotech and Pharma for 2026".
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon